Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

We assessed the safety and efficacy of cabozantinib and nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignances. PATIENTS AND METHODS: Patients received escalating doses of CaboNivo or CaboNivoIpi...

Descripción completa

Detalles Bibliográficos
Autores principales: Apolo, Andrea B., Nadal, Rosa, Girardi, Daniel M., Niglio, Scot A., Ley, Lisa, Cordes, Lisa M., Steinberg, Seth M., Sierra Ortiz, Olena, Cadena, Jacqueline, Diaz, Carlos, Mallek, Marissa, Davarpanah, Nicole N., Costello, Rene, Trepel, Jane B., Lee, Min-Jung, Merino, Maria J., Bagheri, Mohammad Hadi, Monk, Paul, Figg, William D., Gulley, James L., Agarwal, Piyush K., Valera, Vladimir, Chalfin, Heather J., Jones, Jennifer, Streicher, Howard, Wright, John J., Ning, Yangmin M., Parnes, Howard L., Dahut, William L., Bottaro, Donald P., Lara, Primo N., Saraiya, Biren, Pal, Sumanta K., Stein, Mark N., Mortazavi, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605393/
https://www.ncbi.nlm.nih.gov/pubmed/32915679
http://dx.doi.org/10.1200/JCO.20.01652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605393/
https://www.ncbi.nlm.nih.gov/pubmed/32915679
http://dx.doi.org/10.1200/JCO.20.01652

Ejemplares similares